Table 2. Clinical trials with adenosine pathway inhibitors combined with an immune check inhibitor in cancer.
| Target | Drug | Company | Study phase | Tumor | Combination agent | Code |
|---|---|---|---|---|---|---|
| A2AR | PFB509 | Novartis/Palobiofarma | I, Ib | NSCLC | PDR001 (anti-PD-1) | NCT02403193 |
| CPI-444 | Corvus Pharmaceutical | I, Ib | NSCLC, Melanoma, renal cell carcinoma, TNBC, colorectal cancer, bladder cancer | MPDL3280A atezolizumab (anti-PD-1) | NCT02655822 | |
| AZD4635 | AstraZeneca | I | NSCLC, metastatic castrate-resistant prostate carcinoma, colorectal cancer | MEDI4736, durvalumab (anti-PD-L1) | NCT02740985 | |
| PFB509 (NIR178) | Novartis | Ib | Solid tumors and non-Hodgkin lymphoma | PDR001 (anti-PD-1) | NCT03207867 | |
| CD73 | MEDI9447 | MedImmune | I | Selected solid tumor | MEDI4736, durvalumab (anti-PD-L1) | NCT02503774 |
| CPI-006 | Corvus Pharmaceutical | I | NSCLC, RCC, colorectal cancer, TNBC, cervical cancer, ovarian cancer, pancreatic cancer, endometrial cancer, sarcoma, SCC of head and neck, bladder cancer, metastatic castrate-resistant prostate carcinoma | CPI-004 (A2AR antagonist), pembrolizumab (anti-PD-1) | NCT03454451 |
SCC, squamous cell carcinoma; TNBC, triple-negative breast cancer.